Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: Results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group

Blood

Volumn 108, Issue 4, 2006, Pages 1165-1173

  Matloub, Yousif ^a   Lindemulder, Susan ^b   Gaynon, Paul S ^b   Sather, Harland ^b   La, Mei ^b   Broxson, Emmett ^b   Yanofsky, Rochelle ^b   Hutchinson, Raymond ^b   Heerema, Nyla A ^b   Nachman, James ^b   Blake, Marilyn ^b   Wells, Linda M ^b   Sorrell, April D ^b   Masterson, Margaret ^b   Kelleher, John F ^b   Stork, Linda C ^b  

^a University of Wisconsin Children's Hospital   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FOLINIC ACID; HYDROCORTISONE SODIUM SUCCINATE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; APHASIA; ARTICLE; ATAXIA; CANCER INCIDENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DYSARTHRIA; HEALTH CARE ORGANIZATION; HEMIPLEGIA; HUMAN; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; LEUKOENCEPHALOPATHY; NEUROTOXICITY; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCHOOL CHILD; SEIZURE; SLURRED SPEECH; T LYMPHOCYTE; TESTIS; TREATMENT OUTCOME; TRISOMY;

EID: 33747199596     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-12-011809     Document Type: Article

References (77)

1. Aur RJ, Simone J, Hustu HO, et al. Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood. 1971;37:272-281.
2. Pochedly C. Prevention of meningeal leukemia. Review of 20 years of research and current recommendations. Hematol Oncol Clin North Am. 1990;4:951-969.
3. Bleyer WA, Coccia PF, Sather HN, et al. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. J Clin Oncol. 1983;1:317-325.
4. Pinkel D, Woo S. Prevention and treatment of meningeal leukemia in children. Blood. 1994;84:355-366.
5. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Children's Cancer Group report. J Clin Oncol. 1993;11:520-526.
6. Sullivan MP, Chen T, Dyment PG, Hvizdala E, Steuber CP. Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a Pediatric Oncology Group study. Blood. 1982;60:948-958.
7. Bleyer AW. Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep. 1977;61:1419-1425.
8. Komp DM, Fernandez CH, Falletta J, et al. CNS prophylaxis in acute lymphoblastic leukemia: comparison of two methods: a Southwest Oncology Group study. Cancer. 1982;50:1031-1036.
9. van Eys J, Berry D, Crist W, et al. Treatment intensity and outcome for children with acute lymphocytic leukemia of standard risk: a Pediatric Oncology Group study. Cancer. 1989;63:1466-1471.
10. Veerman AJ, Hahlen K, Kamps WA, et al. Dutch Childhood Leukemia Study Group: early results of study ALL VI (1984-1988). Haematol Blood Transfus. 1990;33:473-477.
11. Maloney KW, Shuster JJ, Murphy S, Pullen J, Camitta BA. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia. 2000;14:2276-2285.
12. Silverman LB, Declerck L, Gelber RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000;14:2247-2256.
13. Pui CH, Boyett JM, Rivera GK, et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia. 2000;14:2286-2294.
14. Grindey GB, Nichol CA. Interaction of drugs inhibiting different steps in the synthesis of DNA. Cancer Res. 1972;32:527-531.
15. Grindey GB, Mihich E, Nichol CA. Evaluation of combination chemotherapy in vivo and in culture with I-beta-D-arabinofuranosylcytosine and 1-formylisoquinoline thiosemicarbazone. Cancer Res. 1972;32:522-526.
16. Tattersall MHN, Harrap KR. Combination chemotherapy: the antagonism of methotrexate and cytosine arabinoside. Eur J Cancer. 1973;9:229-232.
17. Edelstein M, Vietti T, Valeriote F. The enhanced cytotoxicity of combinations of 1-beta-D-arabinofuranosylcytosine and methotrexate. Cancer Res. 1975;35:1555-1558.
18. Akutsu M, Furukawa Y, Tsunoda S, Izumi T, Ohmine K, Kano Y. Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro. Leukemia. 2002;16:1808-1817.
19. Lange B, Bostrom B, Cherlow JM, et al. Double-delayed intensification improves event free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2002;99:825-833.
20. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003;101:3809-3817.
21. Pullen J, Boyett J, Shuster J, et al. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol. 1993;11:839-849.
22. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18-24.
23. Uckun FM, Muraguchi A, Ledbetter JA, et al. Biphenotypic leukemic lymphocyte precursors in CD2+CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues. Blood. 1989;73:1000-1015.
24. Pui CH, Behm FG, Crist WM. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood. 1993;82:343-362.
25. Miller DR, Coccia PF, Bleyer WA, et al. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Children's Cancer Study Group. J Clin Oncol. 1989;7:1807-1815.
26. Heerema N, Sather H, Reaman G, et al. Cytogenetic studies of acute lymphoblastic leukemia: clinical correlations results from the Children's Cancer Group. J Assoc Genet Technol. 1998;24:206-212.
27. Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995;9:1985-1989.
28. Mitelman F, ed. ISCN 1995: An International System for Human Cytogenetic Nomenclature 1995. Basel, Switzerland: S. Karger; 1995.
29. Gaynon PS, Desai AA, Bostrom BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer. 1997;80:1717-1726.
30. Simon R. Patient subsets and variation in therapeutic efficacy. Br J Clin Pharmacol. 1982;14:473-482.
31. Xiang AH, Sather HN, Azen SP. Power considerations for testing an interaction in a 2 x k factorial design with a failure time outcome. Control Clin Trial. 1994;15:489-502.
32. Simon R. Some practical aspects of the interim monitoring of clinical trials. Stat Med. 1994;13:1401-1409.
33. DeMets D, Lan G. Interim analysis: the alpha spending function approach. Stat Med. 1994;13:1341-1352.
34. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley and Sons; 1980.
35. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
36. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977;35:1-39.
37. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
38. Stork L, Erdmann GR, Adamson P, et al. Oral 6-thioguanine causes relatively mild and reversible hepatic veno-occlusive disease [abstract]. J Pediatr Hematol Oncol. 1998;20:400a.
39. Hutchinson RJ, Gaynon PS, Sather H, et al. Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881. J Clin Oncol. 2003;21:1790-1797.
40. Inati A, Sallan SE, Cassady JR, et al. Efficacy and morbidity of central nervous system "prophylaxis" in childhood acute lymphoblastic leukemia: eight years' experience with cranial irradiation and intrathecal methotrexate. Blood. 1983;61:297-303.
41. Rimm IJ, Li FC, Tarbell NJ, Winston KR, Sallan SE. Brain tumors after cranial irradiation for childhood acute lymphoblastic leukemia. A 13-year experience from the Dana-Farber Cancer Institute and the Children's Hospital. Cancer. 1987;59:1506-1508.
42. Ochs J, Mulhern R. Long-term sequelae of therapy for childhood acute lymphoblastic leukaemia. Baillieres Clin Haematol. 1994;7:365-376.
43. Ochs JJ. Neurotoxicity due to central nervous system therapy for childhood leukemia. Am J Pediatr Hematol Oncol. 1989;11:93-105.
44. Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;325:1330-1336.
45. Sullivan M, Moon T, Trueworthy R, Vietti T, Humphrey G, Komp D. Combination intrathecal therapy for meningeal leukemia: two versus three drugs. Blood. 1977;50:471-479.
46. Gaynon P, Sensel M, Trigg M, Sather H, Hammond G, Bleyer W. Children's Cancer Group trials in childhood acute lymhoblastic leukemia: 1983-1995. Leukemia. 2000;14:2223-2233.
47. Schrappe M, Camitta B, Pui CH, et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia. 2000;14:2193-2194.
48. Ruggiero A, Conter V, Milani M, et al. Intrathecal chemotherapy with antineoplastic agents in children. Paediatr Drugs. 2001;3:237-246.
49. Zimm S, Collins JM, Miser J, Chatterji D, Poplack DG. Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharmacol Ther. 1984;35:826-830.
50. Spector R. Pharmacokinetics and metabolism of cytosine arabinoside in the central nervous system. J Pharmacol Exp Ther. 1982;222:1-6.
51. Balis FM, Lester CM, Chrousos GP, Heideman RL, Poplack DG. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol. 1987;5:202-207.
52. Bleyer WA. Biology and pathogenesis of CNS leukemia. Am J Pediatr Hematol Oncol. 1989;11:57-63.
53. George SL, Ochs JJ, Mauer AM, Simone JV. The importance of an isolated central nervous system relapse in children with acute lymphoblastic leukemia. J Clin Oncol. 1985;3:776-781.
54. Nesbit ME, D'Angio GJ, Sather H, Hamond D. Central nervous system prophylaxis in leukaemia [letter]. Lancet. 1981;1:322.
55. Ortega JA, Nesbit ME, Sather HN, Robison LL, D'Angio GJ, Hammond GD. Long-term evaluation of a CNS prophylaxis trial - treatment comparisons and outcome after CNS relapse in childhood ALL: a report from the Children's Cancer Study Group. J Clin Oncol. 1987;5:1646-1654.
56. Neale GA, Pui CH, Mahmoud HH, et al. Molecular evidence for minimal residual bone marrow disease in children with 'isolated' extra-medullary relapse of T-cell acute lymphoblastic leukemia. Leukemia. 1994;8:768-775.
57. Goulden N, Langlands K, Steward C, et al. PCR assessment of bone marrow status in 'isolated' extramedullary relapse of childhood B-precursor acute lymphoblastic leukaemia. Br J Haematol. 1994;87:282-285.
58. O'Reilly J, Meyer B, Baker D, Herrmann R, Cannell P, Davies J. Correlation of bone marrow minimal residual disease and apparent isolated extramedullary relapse in childhood acute lymphoblastic leukaemia. Leukemia. 1995;9:624-627.
59. Stork L, Sather H, Nachman J, Hutchinson R, La M, Gaynon P. Intensive therapy 'rescues' children with standard risk ALL (SR-ALL) and slow early response to induction: CCG 1952 results [abstract]. Blood. 2000;96:466a. Abstract 2007.
60. Mahoney DH Jr, Shuster JJ, Nitschke R, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy - a Pediatric Oncology Group study. J Clin Oncol. 1998;16:1712-1722.
61. Bostrom B, Erdman GR, Kamen BA. Systemic methotrexate exposure is greater after intrathecal than after oral administration. J Pediatr Hematol Oncol. 2003;25:114-117.
62. Mahoney DH Jr, Shuster J, Nitschke R, et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. J Clin Oncol. 1998;16:246-254.
63. Graham ML, Shuster JJ, Kamen BA, et al. Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: a pediatric oncology group study. Clin Cancer Res. 1996;2:331-337.
64. Eden OB, Lilleyman JS, Richards S, Shaw MP, Peto J. Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). Br J Haematol. 1991;78:187-196.
65. LeClerc JM, Billett AL, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. J Clin Oncol. 2002;20:237-246.
66. Pui CH, Mahmoud HH, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998;92:411-415.
67. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 2004;104:2690-2696.
68. Schrappe M, Reiter A, Ludwig W-D, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood. 2000;95:3310-3322.
69. Pui CH, Mahmoud HH, Rivera GK, et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood. 1998;92:411-415.
70. Chauvenet AR, Martin P, Bell B, et al. Anti-metabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: Pediatric Oncology Group (POG) Study 9201 [abstract]. Pediatr Blood Cancer. 2005;44:567a.
71. Gajjar A, Harrison PL, Sandlund JT, et al. Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. Blood. 2000;96:3381-3384.
72. Mahmoud HH, Rivera GK, Hancock ML, et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. N Engl J Med. 1993;329:314-319.
73. Bürger B, Zimmermann M, Mann G, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol. 2003;21:184-188.
74. Patte C, Auperin A, Michon J, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97:3370-3379.
75. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999;13:335-342.
76. Ritchey AK, Pollock BH, Lauer SJ, Andejeski Y, Barredo J, Buchanan GR. Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study [published correction appears in J Clin Oncol. 2000;18:703]. J Clin Oncol. 1999;17:3745-3752.
77. Stork LC, Sather H, Hutchinson R, et al. Comparison of mercaptopurine with thioguanine and IT methotrexate with IT "triples" in children with SR-ALL: results of CCG-1952 [abstract]. Blood. 2002;100:156a. Abstract 585.